

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

13 November 2023

Results of Extraordinary General Meeting

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, having successfully completed the MagSense® HER2 Imaging Agent Phase 1 study (IBI10103), provides results of its Extraordinary General Meeting held in Melbourne (and virtually) today.

All resolutions were carried on a poll. Details of the resolutions, proxies received, and the votes cast on the poll in respect of each resolution are set out in the attached summary.

— ENDS —

About Imagion Biosystems

Established in 2017 and headquartered in San Diego, California, US, Imagion Biosystems is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company's lead program has demonstrated its innovative technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Imagion Biosystems' MagSense® pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs.

For more information, visit <https://imaginationbiosystems.com/investor-hub/>

Imagion Biosystems Interactive Investor Hub

Engage with us directly by asking questions, watching video summaries, and seeing what other shareholders have to say about this and past announcements at our Investor Hub:

<https://investorhub.imaginationbiosystems.com/>

Authorisation & Additional information

This announcement was authorised by the Company Secretary of Imagion Biosystems Limited.

Australian Media & Investor Relations:

Geoff Hollis, CFO and Company Secretary
geoff.hollis@imaginationbio.com
+61 438 168 008

U.S. Media Contact

Casie Ost
casie.ost@imaginationbio.com
+1-619-693-4428

Imagion Biosystems Limited

ASX:IBX ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imaginationbiosystems.com | investor@imaginationbio.com



**Imagion Biosystems Limited
Extraordinary General Meeting
Monday, 13 November 2023
Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1. Election of Director - Dr Isaac Bright	Ordinary	92,899,270 83.59%	6,256,747 5.63%	11,981,839 10.78%	4,614,914	114,096,359 94.80%	6,256,747 5.20%	4,614,914	Carried
2. Consolidation of capital of the Company	Ordinary	66,690,019 57.66%	38,092,320 32.94%	10,872,931 9.40%	97,500	86,770,200 69.49%	38,100,320 30.51%	97,500	Carried
3. Approval of the future issue of Subsequent Tranche Convertible Notes and Subsequent Tranche Options to Mercer Street Global Opportunity Fund, LLC	Ordinary	73,126,439 64.30%	27,911,615 24.54%	12,685,002 11.15%	2,029,714	93,471,691 76.03%	29,466,615 23.97%	2,029,714	Carried
4. Approval of issue of Options to Directors	Ordinary	62,639,952 54.75%	40,261,945 35.19%	11,516,839 10.07%	770,034	74,164,791 63.95%	41,816,945 36.05%	770,034	Carried
5. Approval of issue of Options to Dr Isaac Bright	Ordinary	77,743,316 67.26%	26,671,620 23.08%	11,171,334 9.66%	147,500	96,574,900 77.38%	28,226,620 22.62%	147,500	Carried
6. Amendment of Constitution - increase Employee Incentive cap	Special	74,095,193 64.81%	25,687,593 22.47%	14,543,195 12.72%	1,426,789	96,298,638 77.95%	27,242,593 22.05%	1,426,789	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.